These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19941432)

  • 21. [Role of antiviral drugs in containing pandemic influenza. Contribution of recent modelling exercises synthesis prepared by the InVS/Inserm "epidemiology" group - November 2005].
    Lévy-Bruhl D
    Med Mal Infect; 2006 Sep; 36(9):449-53. PubMed ID: 17027218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical economics in the field of influenza--past, present and future.
    Szucs TD
    Virus Res; 2004 Jul; 103(1-2):25-30. PubMed ID: 15163484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of antiviral agents and other measures in an influenza pandemic.
    Groeneveld K; van der Noordaa J
    Neth J Med; 2005 Oct; 63(9):339-43. PubMed ID: 16244380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cost-effectiveness of influenza vaccination The Netherlands].
    Reinders A; Postma MJ; Govaert TM; Sprenger MJ
    Ned Tijdschr Geneeskd; 1997 Jan; 141(2):93-7. PubMed ID: 9036354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research.
    Aiello AE; Coulborn RM; Aragon TJ; Baker MG; Burrus BB; Cowling BJ; Duncan A; Enanoria W; Fabian MP; Ferng YH; Larson EL; Leung GM; Markel H; Milton DK; Monto AS; Morse SS; Navarro JA; Park SY; Priest P; Stebbins S; Stern AM; Uddin M; Wetterhall SF; Vukotich CJ
    Am J Infect Control; 2010 May; 38(4):251-8. PubMed ID: 20226569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.
    Sander B; Bauch CT; Fisman D; Fowler RA; Kwong JC; Maetzel A; McGeer A; Raboud J; Scales DC; Gojovic MZ; Krahn M
    Vaccine; 2010 Aug; 28(38):6210-20. PubMed ID: 20643091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
    Khazeni N; Hutton DW; Garber AM; Owens DK
    Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New vaccine approaches for seasonal and pandemic influenza.
    Palache B
    Vaccine; 2008 Nov; 26(49):6232-6. PubMed ID: 18674583
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maritime health: a case for preventing influenza on the high seas.
    Ruben FL; Ehreth J
    Int Marit Health; 2002; 53(1-4):36-42. PubMed ID: 12608587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influenza: lessons from past pandemics, warnings from current incidents.
    Horimoto T; Kawaoka Y
    Nat Rev Microbiol; 2005 Aug; 3(8):591-600. PubMed ID: 16064053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Public health. Pandemic or not, experts welcome Bush flu plan.
    Kaiser J
    Science; 2005 Nov; 310(5750):952-3. PubMed ID: 16284148
    [No Abstract]   [Full Text] [Related]  

  • 32. Pandemic influenza and renal disease.
    Sears J
    CANNT J; 2007; 17(2):57-60. PubMed ID: 17691713
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of medical interventions for the treatment of healthcare workers during the next influenza pandemic.
    Peterka A
    Am J Disaster Med; 2007; 2(4):169-71. PubMed ID: 18488830
    [No Abstract]   [Full Text] [Related]  

  • 34. Strategies for containing a global influenza pandemic.
    Flahault A; Vergu E; Coudeville L; Grais RF
    Vaccine; 2006 Nov; 24(44-46):6751-5. PubMed ID: 16843574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feds to stockpile antivirals as pandemic "speed bump".
    Lett D
    CMAJ; 2005 Apr; 172(9):1167. PubMed ID: 15788559
    [No Abstract]   [Full Text] [Related]  

  • 36. Antiviral agents for influenza: a comparison of cost-effectiveness data.
    Lynd LD; Goeree R; O'Brien BJ
    Pharmacoeconomics; 2005; 23(11):1083-106. PubMed ID: 16277546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmaco-economics of anti-influenza vaccinations].
    Jahnz-Rózyk K
    Pol Merkur Lekarski; 2003 Jun; 14(84):679-81. PubMed ID: 14524303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic analysis of pandemic influenza vaccination strategies in Singapore.
    Lee VJ; Tok MY; Chow VT; Phua KH; Ooi EE; Tambyah PA; Chen MI
    PLoS One; 2009 Sep; 4(9):e7108. PubMed ID: 19771173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investment in antiviral drugs: a real options approach.
    Attema AE; Lugnér AK; Feenstra TL
    Health Econ; 2010 Oct; 19(10):1240-54. PubMed ID: 19816857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
    Lee VJ; Phua KH; Chenm MI; Chow A; Ma S; Goh KT; Leo YS
    Emerg Infect Dis; 2006 Jan; 12(1):95-102. PubMed ID: 16494724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.